Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy

Journal of Clinical Oncology

Volumn 14, Issue 2, 1996, Pages 343-350

  Pujade Lauraine, E ^a   Guastalla, J P ^a   Colombo, N ^a   Devillier, P ^a   Francois E ^a   Fumoleau, P ^a   Monnier, A ^a   Nooy, M ^a   Mignot, L ^a   Bugat, R ^a   Marques, C ^a   Mousseau, M ^a   Netter, G ^a   Maloisel, F ^a   Larbaoui, S ^a   Brandely, M ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GAMMA INTERFERON;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NAUSEA; OVARY CANCER; PERITONITIS; PRIORITY JOURNAL; SECOND LOOK SURGERY; VOMITING;

EID: 9044223660     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.2.343     Document Type: Article

References (54)

1. Piver MS (ed): Ovarian Malignancies: Diagnostic and Therapeutic Advances. London, United Kingdom, Churchill Livingstone, 1987, pp 109-128
2. Louie KG, Ozols RF, Myers CE, et al: Long term results of a cis-platin containing combination chemotherapy regimen (Chex-UP) for the treatment of advanced ovarian carcinoma. J Clin Oncol 4:1579-1585, 1986
3. Howell WB, Pleifle CE, Wung WE, et al: Intraperitoneal cis-diaminedichloroplatinum with systemic thiosulfate protection. Cancer Res 43:1426-1431, 1983
4. Ten Bokkel Huinink WW, Dubbelman R, Franklin A, et al: Experimental and clinical results with intraperitoneal cisplatin. Semin Oncol 12:43-46, 1985 (suppl 4)
5. Markman M, Cleary S, Lucas W, et al: IP chemotherapy employing a regimen of cisplatin, cytarabine and bleomycin. Cancer Treat Rep 70:755-760, 1986
6. Piver MS, Lele SB, Marchetti DL, et al: Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma. J Clin Oncol 6:1679-1684, 1988
7. Oldham RK: Biologicals and biological response modifiers: Fourth modality of cancer treatment. Cancer Treat Rep 68:221-223, 1984
8. Allavena P, Grandi M, D'Incalci M, et al: Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin 2 activated killer cells and by activated monocytes. Int J Cancer 40:104-107, 1987
9. Berek JS, Hacker NF, Lichtenstein A, et al: Intraperitoneal recombinant α-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer. Cancer Res 45:447-4453, 1985
10. Lembersby B, Baldisseri M, Kunschner A, et al: Phase I-II study of intraperitoneal (IP) low dose of interleukin 2 (IL2) in refractory stage III ovarian cancer (OC). Proc Am Soc Clin Oncol 8:636, 1989 (abstr)
11. Bonnem EM, Oldham RK: γ-Interferon: Physiology and speculation on its role in medicine. J Biol Response Modif 6:275-283, 1987
12. Celada A, Gray PW, Rinkerknecht E, et al: Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. J Exp Med 55:160-164, 1984
13. Saito T, Berens ME, Welander CE: Direct and indirect effects of human recombinant γ-interferon on tumor cells in a clonogenic assay. Cancer Res 46:1142-1147, 1984
14. Balkwill F, Ward B, Moodie E, et al: Therapeutic potential of tumor necrosis factor-α and γ-interferon in experimental human ovarian cancer. Cancer Res 47:4755-4758, 1987
15. Malik STA, Knowles RG, East N, et al: Antitumor activity of gamma-interferon in ascitic and solid tumor models of human ovarian cancer. Cancer Res 51:6643-6649, 1991
16. Wallich R, Bulbuc N, Hammerling GJ, et al: Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315:301-303, 1985
17. Tanaka K, Hayashi H, Hamada C, et al: Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells. Proc Natl Acad Sci USA 83:8723-8727, 1986
18. Weber J, Jay G, Tanaka K, et al: Immunotherapy of a murine tumor with interleukin-2 increased sensitivity after MHC class I gene transfection. J Exp Med 166:1716-1733, 1987
19. Allavena P, Peccatori F, Maggioni D, et al: Intraperitoneal recombinant γ-interferon in patients with recurrent ascitic ovarian carcinoma: Modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res 50:7318-7323, 1990
20. Mannel DN, Falk W: Interferon-gamma is required in activation of macrophages for cytotoxicity. Cell Immunol 79:396-402, 1983
21. Saito T, Berens ME, Welander CE: Characterization of the indirect antitumor effects of γinterferon using ascites-associated macrophages in a human tumor clonogenic assay. Cancer Res 47:673-679, 1987
22. Colombo N, Peccatori F, Paganin C, et al: Anti-tumor and immunomodulatory activity of intraperitoneal interferon-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy. Int J Cancer 51:42-46, 1992
23. Welander CE, Homesley HD, Reich SD, et al: A phase II study of the efficacy of recombinant interferon gamma in relapsing ovarian adenocarcinoma. Am J Clin Oncol 2:455-460, 1988
24. D'Acquisto R, Markman M, Hakes T, et al: A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma. J Clin Oncol 6:689-695, 1988
25. Belardelli F, Gresser I, Maury C, et al: Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend leukemia cells. Int J Cancer 30:813-820, 1982
26. Markman M, Reichman B, Hakes T, et al: Intraperitoneal chemotherapy in the management of ovarian cancer. Cancer 71:1465-1570, 1993
27. Berek JS, Hacker N, Lichtenstein A, et al: Intraperitoneal immunotherapy of epithelial ovarian cancer with Corynebacterium parvum. Am J Obstet Gynecol 152:1003-1009, 1985
28. Markman M, Hakes T, Reichman B, et al: Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma. J Clin Oncol 9:204-210, 1991
29. Willemse P, De Vries E, Mulder N, et al: Intraperitoneal human recombinant interferon alpha 2b in minimal residual oarian cancer. Eur J Cancer 26:353-358, 1990
30. Nardi M, Cognetti F, Pollera CF, et al: Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: A phase II study. J Clin Oncol 8:1036-1041, 1990
31. Berek JS, Welander C, Schink JC, et al: A phase I-II trial of intraperitoneal cisplatin and α-interferon in patients with persistent epithelial ovarian cancer. Gynecol Oncol 40:237-243, 1991
32. Markman M, Reichman B, Hakes T, et al: Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin. J Clin Oncol 9:1801-1805, 1991
33. Kaye S, Lewis CR, Paul J, et al: Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 341:329-333, 1992
34. Ovarian Cancer Meta-Analysis Project: Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. J Clin Oncol 9:1668-1674, 1991
35. Nagel JE, Chopra RK, Chrest FJ, et al: Decreased proliferation, interleukin 2 synthesis, and interleukin 2 receptor expression in phytohemagglutinin-stimulated cells from elderly donors. J Clin Invest 81:1096-1102, 1988
36. Chandra RK: Effect of vitamin and trace-element supplementation on immune responses and infection in elderly subjects. Lancet 340:1124-1127, 1992
37. Jiao H, Soejima Y, Ohe Y, et al: Differential macrophage-mediated cytotoxicity to P388 leukemia cells and its drug-resistant cells examined by a new MTT assay. Leuk Res 16:1175-1180, 1992
38. Piccart M, Speyer JL, Markman M, et al: Intraperitoneal chemotherapy: Technical experiences at five institutions. Semin Oncol 8:1618-1629, 1985
39. Lotze MT, Custer MC, Rosenberg SA: Intraperitoneal administration of interleukin-2 in patients with cancer. Arch Surg 121:1373-1379, 1986
40. Rambaldi A, Introna M, Colotta F, et al: Intraperitoneal administration of interferon β in ovarian cancer patients. Cancer 56:294-301, 1985
41. Elias JA, Jimenez SA, Freundlich B: Recombinant gamma, alpha, and beta interferons regulation of human lung fibroblast proliferation. Am Rev Respir Dis 135:62-65, 1987
42. Kähäri VM, Heino J, Vuorio T, et al: Interferon-α and interferon-gamma reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture. Biochem Biophys Acta 968:45-50, 1988
43. Giri SN, Hyde DM, Marafino BJ: Ameliorating effect of murine gamma-interferon on bleomycin-induced lung collagen fibrosis in mice. Biochem Med Meth Biol 36:194-197, 1986
44. Granstein RD, Murphy FG, Margolis RG, et al: Gamma interferon inhibits collagen synthesis in vivo in the mouse. J Clin Invest 79:1254-1258, 1987
45. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al: Long-term survival in ovarian cancer. Mature data from the Netherlands Joint Study Group for ovarian cancer. Eur J Cancer 27:1367-1372, 1991
46. Björkholm E, Petersson F, Einhorn N, et al: Long-term follow-up and prognostic factors in ovarian carcinoma: The Radiumhemmet series 1958-1973. Acta Radiol Oncol Radiat Phys Biol 21:413-419, 1982
47. Lippman SM, Alberts DS, Slymen DJ, et al: Second-look laparotomy in epithelial ovarian carcinoma. Cancer 61:2571-2577, 1988
48. De Gramont A, Drolet Y, Varette C, et al: Survival after second-look laparotomy in advanced ovarian epithelial cancer. Eur J Cancer Clin Oncol 25:251-257, 1989
49. Chambers SK, Chambers JT, Kohom EI, et al: Evaluation of the role of second-look surgery in ovarian cancer. Obstet Gynecol 72:404-408, 1988
50. Van der Burg MEL, van Lent M, Kobierska A, et al: Intervention debulking surgery does improve survival in advanced epithelial ovarian cancer; An EORTC Gynecological Cancer Cooperative Group (GCCG) study. Proc Am Soc Clin Oncol 12:258, 1993 (abstr 818)
51. Saito T, Berens ME, Welander CE: Interferon gamma and cytotoxic agents studied in combination using a soft agarose human tumor clonogenic assay. Cancer Chemother Pharmacol 19:233-239, 1987
52. Mutch DG, Massard SL, Kao MS, et al: Proliferative and antiproliferative effects of interferon-γ and tumor necrosis factor-α on cell lines derived from cervical and ovarian malignancies. Am J Obstet Gynecol 163:1920-1924, 1990
53. 4-bearing mice. J Interferon Res 8:241-249, 1988
54. Silagi S, Dutkowski R, Schaeger A, et al: Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon gamma. Int J Cancer 41:315-322, 1988